-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The body of people with type 2 diabetes no longer uses insulin effectively to control blood sugar
.
Dipeptidyl peptidase-4 inhibitors, also known as gliptin, can be prescribed when other diabetes drugs are not working
"Patients with diabetes have been shown to have a higher risk of Alzheimer's disease, possibly due to high blood sugar levels, which are related to the formation of amyloid beta protein in the brain," said study author Dr.
Phil Hyu Lee of Yonsei University School of Medicine in Seoul
.
"Our research not only showed that people who took dipeptidyl peptidase-4 inhibitors to lower blood sugar levels had less amyloid in their brains overall, but also showed that brain regions related to Alzheimer's disease Has lower levels of amyloid
The study involved 282 people with an average age of 76 years and were followed up for 6 years
.
All have been diagnosed with preclinical, early or possible Alzheimer's disease
Participants’ brain scans to measure the amount of amyloid in the brain
.
The researchers found that the average number of amyloid plaques in the brains of diabetic patients who took medication was lower than that of diabetic patients and non-diabetic patients who did not take medication
.
On average, all participants took a thinking and memory test called the Mini Mental State Test (MMSE) every 12 months for two and a half years
.
Questions include getting a person to count down from 100 to 7, or copy a picture on a piece of paper
The researchers found that the MMSE scores of diabetic patients who took medications decreased by an average of 0.
87 points per year, while the MMSE scores of diabetic patients who did not take medications decreased by an average of 1.
65 points per year
.
People without diabetes have an average annual decline of 1.
When the researchers adjusted for other factors that might affect test scores, they found that people who took the drug lost 0.
77 points a year, which was slower than those who didn't take the drug
.
Lee said: "Our results show that compared with people without diabetes, people who take these drugs have less amyloid in their brains and have fewer cognitive declines, which raises the possibility.
That is, these drugs may also be beneficial for people without diabetes who have thinking and memory problems
.
More research is needed to prove whether these drugs have neuroprotective properties for everyone
One limitation of this study is that the data cannot show the accumulation of amyloid in the brains of participants over time
.
This study did not show causality
Seong Ho Jeong, Hye Ryun Kim, Jeonghun Kim, Hankyeol Kim, Namki Hong, Jin Ho Jung, Kyoungwon Baik, Hanna Cho, Chul Hyoung Lyoo, Byoung Seok Ye, Young H.
Sohn, Joon-Kyung Seong, Phil Hyu Lee.
